AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures

As it has been tussling over licensing checks and trying to gain a reprieve, AstraZeneca quietly announced in the midst of its quarterly update this morning that selumetinib has once again missed the mark in a cancer test.